1. Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults

   • Donna Rowen
   • Clara Mukuria
   • Allan Wailoo

   Current Opinion 16 March 2022 Pages: 479 - 488

2. Assessments of the Value of New Interventions Should Include Health Equity Impact

   • Jeroen P. Jansen
   • Thomas A. Trikalinos
   • Kathryn A. Phillips

   Current Opinion Open access 03 March 2022 Pages: 489 - 495

   

3. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches

   • Elamin H. Elbasha

   Practical Application Open access 09 February 2022 Pages: 497 - 507

   

4. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Sabine E. Grimm
   • Willem Witlox
   • Manuela A. Joore

   Review Article Open access 19 October 2021 Pages: 509 - 518

5. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

   • Min Huang
   • Amin Haiderali
   • Joyce O’Shaughnessy

   Systematic Review Open access 03 February 2022 Pages: 519 - 558

   

6. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England

   • K. Ray Chaudhuri
   • A. Simon Pickard
   • Anette Schrag

   Original Research Article Open access 21 March 2022 Pages: 559 - 574

   

7. Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Sabine E. Grimm
   • Willem Witlox
   • Manuela A. Joore

   Correction Open access 01 April 2022 Pages: 575 - 575